MedTrace Logo

Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test

NCT05176145 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2023-10-13

No results posted yet for this study

Summary

European, multicenter clinical trial with VisioCyt®, an in vitro diagnostic medical device. VisioCyt® is an innovative solution for the early diagnosis of bladder cancer.

Conditions

  • Non-muscle Invasive Bladder Cancer (NMIBC)

Interventions

DEVICE

VisioCyt®

* Cytological and endoscopic examination is planned as part of the usual management of patients under surveillance of Non-muscle invasive bladder cancer (NMIBC), according to the CCAFU guidelines. * Urine collection for conventional cytology and VisioCyt® test

Sponsors & Collaborators

  • FONDATION FORCE POUR L'INNOVATION ET LA RECHERCHE EN SANTE

    collaborator UNKNOWN

  • Vitadx

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-05
Primary Completion
2025-02-01
Completion
2025-05-31

Countries

  • Belgium
  • France
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05176145 on ClinicalTrials.gov